David Protein Says ‘Diet’ Trends Are Over, GLP-1s Upend Markets
David Rahal, founder and CEO of David Protein, argues GLP-1 drugs have upended the diet-trend cycle, reshaping how br...
This tag page compiles 4 articles on GLP-1 trends, pricing, and weight-loss stock impacts, helping you understand how drug costs and market moves affect personal finances.
50 articlesDavid Rahal, founder and CEO of David Protein, argues GLP-1 drugs have upended the diet-trend cycle, reshaping how br...
In the race to dominate obesity drugs, Novo Nordisk and Eli Lilly are frontrunners. This guide analyzes who has the e...
A new Medicare bridge program could lower GLP-1 drug bills to about $50 a month for eligible seniors. Here’s what you...
The ADA conference spotlighted Lilly and Novo Nordisk in the GLP-1 race. This deep dive explains what the claims mean...
The July 4 grilling season unfolds amid higher meat prices and a wave of GLP-1 drug use that is reshaping what househ...
UPS is investing $48 million to add 27 temperature-controlled facilities, accelerating GLP-1 deliveries and reshaping...
Pfizer is quietly building a GLP-1 obesity pipeline that could alter the competitive landscape, while investors seek ...
Lilly leads the GLP-1 obesity wave as Pfizer rebuilds with deals and repurposed assets. Q1 2026 results underscore tw...
A new milestone for obesity treatment arrives as Novo Nordisk's Wegovy Pill hits 3 million prescriptions. This articl...
This deep dive looks at why Lilly stock may be a standout pick for growth-focused investors. From a dominant obesity ...
Two Invesco health care ETFs offer different paths to play the GLP-1 revolution. This guide breaks down how invesco's...
Seeking a stock with growth, resilience, and optionality? This article lays out three strong reasons to consider Lill...